Close Menu

cervical cancer

With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing

The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.

Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round. 

The Series A financing will be used to commercialize its lung cancer diagnostic test and develop tests for other cancers. 

The clinical diagnostics company will use the funds to invest in a new UK-based manufacturing facility and to accelerate global growth.

The contract includes a milestone of approval by the Chinese Food and Drug Agency within the next three years.

The test for cervical cancer screening previously received the IVD mark and US Food and Drug Administration approval on the Cobas 4800 system.

A special issue of Preventive Medicine tackles issues surrounding HPV testing as a primary screening method for cervical cancer in a range of clinical settings.

The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.

Pages